They cannot by themselves establish: A safe human amount A safe route of administration Long-term human safety Interaction risks Reproductive or developmental safety Clinical effectiveness Which individuals, if any, might be suitable for an authorised use The number of animal papers should not be presented as equivalent to a programme of large, well-controlled human clinical trials
By day 28, you're injecting a solution where nearly half the active compound has degraded into inactive peptide fragments and free copper ions
For the low 1.6 mg dose, use 5 units per injection
Tendon injuries Rotator cuff strains, tennis elbow, Achilles tendonitis, and patellar tendonitis respond well to BPC-157s ability to promote angiogenesis and collagen production in connective tissues
Visible Results
We advise against use in patients with active cancer, cardiovascular disease, autoimmune disorders, liver or kidney disease, clotting issues, pregnancy or breastfeeding, or those under age 20